Agras WS, Dorian B, Kirkley BG, Arnow B, Backman J. Imipramine in the treatment of bulimia: A double-blind controlled study. International Journal of Eating Disorders. 1987;6:29–38.
Agras WS, Schneider JA, Arnow B, Raeburn SD, Telch CF. Cognitive-behavioral and response-prevention treatments for bulimia nervosa. Journal of Consulting & Clinical Psychology. 1989;57:215–221. [PubMed: 2708607]
Agras WS, Rossiter EM, Arnow B, Schneider JA, Telch CF, Raeburn SD, Bruce B, Perl M, Koran LM. Pharmacologic and cognitive-behavioral treatment for bulimia nervosa: A controlled comparison. American Journal of Psychiatry. 1992;149:82–87. [PubMed: 1728190]
Agras WS, Rossiter EM, Arnow B, Telch CF, Raeburn SD, Bruce B, Koran LM. One-year follow-up of psychosocial and pharmacologic treatment for bulimia nervosa. Journal of Clinical Psychiatry. 1994;55:179–183. [PubMed: 8071266]
Agras WS, Telch CF, Arnow B, Eldredge KL, Detzer MJ, Henderson J, Marnell M. Does interpersonal therapy help patients with binge eating disorder who fail to respond to cognitive-behavioral therapy? Journal of Consulting & Clinical Psychology. 1995;63:356–360. [PubMed: 7608347]
Agras WS, Walsh BT, Fairburn CG, Wilson CT, Kramer HC. A multi-centre comparison of Cognitive-Behavioral Therapy and Interpersonal Psychotherapy for bulimia nervosa. Archives of General Psychiatry. 2000a;54:459–465. [PubMed: 10807486]
Agras WS, Crow SJ, Halmi KA, Mitchell JE, Wilson GT, Kraemer HC. Outcome predictors for the cognitive behavior treatment of bulimia nervosa: Data from a multisite study. American Journal of Psychiatry. 2000;157(8):1302–1308. [PubMed: 10910795]
Agras WS. The consequences and costs of the eating disorders. 2001;24(2):371–379. [PubMed: 11416936]
APA. American Psychiatric Association Work Group on Eating Disorders. Practice guideline for the treatment of patients with eating disorders (revision 2000) American Journal of Psychiatry. 1994;157:1–39. [PubMed: 10642782]
Anstine D, Grinenko D. Rapid screening for disordered eating in college-aged females in the primary care setting. Journal of Adolescent Health. 2000;26(5):338–342. [PubMed: 10775826]
Arii I, Yamashita T, Kinoshita M, Shimizu H, Nakamura M, Nakajima T. Treatment for inpatients with anorexia nervosa: Comparison of liquid formula with regular meals for improvement from emaciation. Psychiatry & Clinical Neurosciences. 1996;50:55–59. [PubMed: 8783376]
Arnold LM, McElroy S, Hudson JI, Welge JA, Bennett AJ, Keck PE. A placebo-controlled, randomised trial of fluoxetine in the treatment of binge-eating disorder. Journal of Clinical Psychiatry. 2002;63:1028–1033. [PubMed: 12444817]
Attia E, Haiman C, Walsh BT, Flater SR. Does Fluoxetine augment the inpatient treatment of anorexia nervosa? American Journal of Psychiatry. 1998;155:548–551. [PubMed: 9546003]
Babyak M, et al. Exercise treatment for major depression: Maintenance of therapeutic benefit at 10 months. Psychosomatic Medicine. 2000;62:633–638. [PubMed: 11020092]
Bachar E, Latzer Y, Kreitler S, Berry EM. Empirical comparison of two psychological therapies. Journal of Psychotherapy Practise and Research. 1999;8:115–128. [PMC free article: PMC3330539] [PubMed: 10079459]
Bachrach LK, Guido D, Katzman D, Litt IF, Marcus R. Decreased bone density in adolescent girls with anorexia nervosa. Pediatrics. 1990;86:440–447. [PubMed: 2388792]
Bailer U, de Zwaan M, Leisch F, Strnad A, Lennkh-Wolfsberg C, El-Giamal N, Hornik K, Kasper S. Guided self-help versus cognitive behavioural group therapy in the treatment of bulimia nervosa. British Journal of Psychiatry. 2002
Beglin SJ, Fairburn CG. What is meant by the term ‘binge’? American Journal of Psychiatry. 1992;149(1):123–124. [PubMed: 1728161]
Ben-Tovim DI, Walker K, Gilchrist P, Freeman R, Kalucy R, Esterman A. Outcome in patients with eating disorders: A five-year study. The Lancet. 2001;357(9264):1254–1257. [PubMed: 11418150]
Bergh C, Brodin U, Lindberg G, Sodersten P. Randomised controlled trial of a treatment for anorexia and bulimia nervosa. Proceedings of the National Academy of Sciences of the United States of America. 2002;99:9486–9491. [PMC free article: PMC123167] [PubMed: 12082182]
Berlin JA. Does blinding of readers affect the results of meta-analyses? University of Pennsylvania Meta-analysis Blinding Study Group. Lancet. 1997;350(9072):185–186. [PubMed: 9250191]
Beumont PJ, Abraham SF, Argall WJ, George CW, Glaun DE. The onset of anorexia nervosa. Australian & New Zealand Journal of Psychiatry. 1978;12:145–149. [PubMed: 281928]
Beumont PJ, Russell JD, Touyz SW, Buckley C, Lowinger K, Talbot P, Johnson GFS. Intensive nutritional counselling in bulimia nervosa: A role for supplementation with fluoxetine? Australian & New Zealand Journal of Psychiatry. 1997;31:514–524. [PubMed: 9272261]
Bianchi AS, Toy EC, Baker IB. The evaluation of involuntary weight loss. Primary Care Update for Ob/Gyns. 1998;5(6):263–267.
Biederman J, Herzog D, Rivinus TM, Harper GP, Ferber RA, Rosenbaum JF, Harmatz JS, Tondorf R, Orsulak PJ, Schildkraut JJ. Amitriptyline in the treatment of anorexia nervosa: A double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology. 1985;5:10–16. [PubMed: 3973067]
Biller BM, Saxe V, Herzog DB, Rosenthal DI, Holzman S, Klibanski A. Mechanisms of osteoporosis in adult and adolescent women with anorexia nervosa. Journal of Clinical Endocrinology and Metabolism. 1989;68:548–554. [PubMed: 2493036]
Birchall H, Palmer RL, Waine J, Gadsby K, Gatward N. Intensive day programme treatment for severe anorexia nervosa – the Leicester experience. Psychiatric Bulletin. 2002;26:334–336.
Birmingham CL, Goldner EM, Bakan R. Controlled trial of zinc supplementation in anorexia nervosa. International Journal of Eating Disorders. 1994;15:251–255. [PubMed: 8199605]
Bizeul C, Sadowsky N, Rigaud D. The prognostic value of initial EDI scores in anorexia nervosa patients: A prospective follow-up study of 5–10 years. Eating Disorder Inventory. European Psychiatry. 2001;16(4):232–238. [PubMed: 11418274]
Braun DL, Sunday SR, Halmi KA. Psychiatric comorbidity in patients with eating disorders. Psychological Medicine. 1994;24:859–867. [PubMed: 7892354]
Briggs AH, Goeree R, Blackhouse G, O’Brien BJ. Probabilistic analysis of cost-effectiveness models: Choosing between treatment strategies for gastroesophageal reflux disease. Medical Decision Making. 2002 July–August:290–308. [PubMed: 12150595]
Briggs AH, Gray AM. Handling uncertainty when performing economic evaluation of health care interventions. NICE Health Technology Assessment. 1999;3(2) [PubMed: 10448202]
Brinch M, Isager T, Tolstrup K. Anorexia nervosa and motherhood: Reproduction pattern and mothering behaviour of 50 women. Acta Psychiatrica Scandinavica. 1988;77:611–617. [PubMed: 3269214]
Brinch M, Isager T, Tolstrup K. Patients’ evaluation of their former treatment for anorexia nervosa (AN). Nordisk psykiatrisk tidsskrift. Nordic Journal of Psychiatry. 1988;42:445–448.
British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary (BNF) 2003;45
Brown A. Eating disorders – the developing mixed economy. Mental Health Research Review. 1997;4:32–35.
Bryant-Waugh R, Knibbs J, Fosson A, Kaminski Z, Lask B. Long-term follow-up of patients with early onset anorexia nervosa. Archives of Disease in Childhood. 1988;63(1):5–9. [PMC free article: PMC1779342] [PubMed: 3348649]
Bryant-Waugh R. Overview of eating disorders. In: Lask B, Bryant-Waugh R, editors. Anorexia nervosa and related eating disorders in childhood and adolescence. Hove: Psychology Press; 2000. pp. 27–40.
Bryant-Waugh RJ, Lask BD. Eating disorders in children. Journal of Child Psychoogy & Psychiatry. 1995;36(2):191–202. [PubMed: 7759586]
Bryant-Waugh RJ, Lask BD, Shafran RL, Fosson AR. Do doctors recognise eating disorders in children? Archives of Disease in Childhood. 1992;67(1):103–105. [PMC free article: PMC1793541] [PubMed: 1739320]
Bulik CM, Sullivan PF, Carter FA, McIntosh VV, Joyce PR. The role of exposure with response prevention in the cognitive-behavioural therapy for bulimia nervosa. Psychol Med. 1998;28(3):611–623. [PubMed: 9626717]
Bulik CM, Sullivan PF, Fear JL, Pickering A, Dawn A, McCullin M. Fertility and reproduction in women with anorexia nervosa: A controlled study. Journal of Clinical Psychiatry. 1999;60:130–135. [PubMed: 10084645]
Bulik CM, Sullivan PF, Wade T, Kendler KS. Twin studies of eating disorders: A review. International Journal of Eating Disorders. 2000;27:1–20. [PubMed: 10590444]
Bulik CM, Sullivan PF, Fear JL, Pickering A. Outcome of anorexia nervosa: Eating attitudes, personality and parental bonding. International Journal of Eating Disorders. 2002;28(2):139–147. [PubMed: 10897075]
Burns T, Crisp AH. Outcome of anorexia nervosa in males. British Journal of Psychiatry. 1984;145:319–325. [PubMed: 6478127]
Buston K. Adolescents with mental health problems: What do they say about health services? Journal of Adolescence. 2002;25:231–242. [PubMed: 12069437]
Carney CP, Andersen AE. Eating disorders. Guide to medical evaluation and complications. Psychiatric Clinics of North America. 1996;19(4):657–679. [PubMed: 8933601]
Carruba MO, Cuzzolaro M, Riva L, Bosello O, Liberti S, Castra R, Dalle Grave R, Santonastaso P, Garosi V, Nisoli E. Efficacy and tolerability of moclobemide in bulimia nervosa: A placebo-controlled trial. International Clinical Psychopharmacology. 2001;16:27–32. [PubMed: 11195257]
Carter J, Moss Screening for anorexia and bulimia nervosa in a college population: Problems and limitations. Addictive Behaviour. 1984;9(4):417–419. [PubMed: 6598003]
Carter J, Fairburn CC. Cognitive behavioral self-help for binge eating disorder: A controlled effectiveness study. Journal of Consulting & Clinical Psychology. 1998;66:616–623. [PubMed: 9735577]
Carter J, Olmsted M, Kaplan AS, McCabe RE, Mills JS, Aime A. Self-help for bulimia nervosa: A randomised controlled trial. American Journal of Psychiatry. 2003;160:973–978. [PubMed: 12727703]
Casper RC. Introduction to special issue. Journal of Youth and Adolescence. 1996;25:413–418.
Casper Regina C, Jabine LN. An eight-year follow-up: Outcome from adolescent compared to adult onset anorexia nervosa. Journal of Youth & Adolescence. 1996;25(4):499–517.
Castro J, Lazaro L, Pons F, Halperin I, Toro J. Adolescent anorexia nervosa: The catch-up effect in bone mineral density after recovery. Journal of the American Academy of Child and Adolescent Psychiatry. 2001;40:1215–1221. [PubMed: 11589535]
Channon S, de Silva P, Hemsley D, Perkins R. A controlled trial of cognitive-behavioural and behavioural treatment of anorexia nervosa. Behavioural Research and Therapy. 1989;27:529–535. [PubMed: 2684134]
Chen E, Touyz SW, Beumont PJ, Fairburn CG, Griffiths R, Butow P, Russell J, Schotte DE, Gertler R, Basten C. Comparison of group and individual cognitive-behavioural therapy for patients with bulimia nervosa. International Journal of Eating Disorders. 2003;33:241–254. [PubMed: 12655619]
Cochrane Collaboration. Review Manager (RevMan) [Computer program] Version 4.2 for Windows. Oxford, England: The Cochrane Collaboration; 2003.
Cole, et al. Body mass index reference curves for the UK, 1990. Arch Dis Child. 1995;73(1):25–29. [PMC free article: PMC1511150] [PubMed: 7639544]
Cole TJ, Bellizzi MC, Flegal KM, et al. Establishing a standard definition for child overweight and obesity worldwide: International survey. British Medical Journal. 2000;320:1240–1243. [PMC free article: PMC27365] [PubMed: 10797032]
Cooper Z, Fairburn C. The Eating Disorder Examination: A semi-structured interview for the assessment of the specific psychopathology of eating disorders. International Journal of Eating Disorders. 1987;6:1–8.
Cooper PJ, Steere JA. Comparison of two psychological treatments for bulimia nervosa: Implications for models of maintenance. Behaviour Research and Therapy. 1995;33:875–885. [PubMed: 7487847]
Cooper PJ, Coker S, Fleming C. An evaluation of the efficacy of supervised cognitive behavioral self-help bulimia nervosa. J. Psychosom Res. 1996;40(3):281–287. [PubMed: 8861124]
Cooper PJ, Watkins B, Bryant-Waugh R, Lask B. The nosological status of early onset anorexia nervosa. Psychol Med. 2002;32(5):873–880. [PubMed: 12171381]
Cotton MA, Ball C, Robinson P. Four simple questions can help screen for eating disorders. Journal of General Internal Medicine. 2003 [PMC free article: PMC1494802] [PubMed: 12534764]
Crisp AH, Callender JS, Halek C, Hsu LKG. Long-term mortality in anorexia nervosa: A 20-year follow-up of the St George’s and Aberdeen Cohorts. British Journal of Psychiatry. 1992;161:80–87. [PubMed: 1638303]
Crisp AH, Hsu LK, Stonehill E. Personality, body weight and ultimate outcome in anorexia nervosa. Journal of Clinical Psychiatry. 1979;40(8):332–325. [PubMed: 468756]
Crisp AH, Norton K, Gowers S, Halek C, Bowyer C, Yeldham D, Levett G, Bhat A. A controlled study of the effect of therapies aimed at adolescent and family psychopathology in anorexia nervosa. British Journal of Psychiatry. 1991;59:325–333. [PubMed: 1958942]
Crisp AH. The dyslipophobias: A view of the psychopathologies involved and the hazards of construing anorexia nervosa and bulimia nervosa as ‘eating disorders’ Proc Nutr Soc. 1995;54(3):701–709. [PubMed: 8643707]
Crisp AH. Stigmatisation of people with mental illnesses. British Journal of Psychiatry. 2000;177:4–7. [PubMed: 10945080]
Crow S, Praus B, Thuras P. Mortality from eating disorders – A 5–10-year record linkage study. International Journal of Eating Disorders. 1999;26:97–101. [PubMed: 10349590]
Crow SJ, Peterson CB. The economic and social burden of eating disorders: A review. In: Maj M, et al., editors. Eating Disorders. John Wiley & Sons Ltd; 2003.
Dally PJ. Anorexia Nervosa. London: Heinemann Medical Books; 1969.
Danziger Y, Mukamel M, Zeharia A, Dinari G, Mimouni M. Stunting of Growth in Anorexia nervosa during the prepubertal and pubertal period. Israeli Journal of Medical Science. 1994;30:581–584. [PubMed: 8045735]
Dare C, Crowther C. Living dangerously: Psychoanalytic psychotherapy of anorexia nervosa. In: Szmukler G, Dare C, Treasure J, editors. Eating disorders: Handbook of theory, treatment and research. Chichester: John Wiley & Sons; 1995.
Dare C, Eisler I, Russell G, Treasure J, Dodge L. Psychological therapies for adults with anorexia nervosa: Randomised controlled trial of out-patient treatments. British Journal of Psychiatry. 2001;178:216–221. [PubMed: 11230031]
Deeks JJ. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Statistics in Medicine. 2002;21(11):1575–1600. [PubMed: 12111921]
Deering S. Eating disorders: Recognition, evaluation and implications for obstetrician/gynecologists. Primary Care Update for Ob/Gyns. 2000;8(1):31–35. [PubMed: 11164350]
Department of Health. A commitment to carers; Help for relatives, partners and friends of people with a mental health problem. 2003. http://www.rethink.org/carers/
DerSimonian R, Laird N. Meta-analysis in Clinical Trials. Controlled Clinical Trials. 1986;7:177–188. [PubMed: 3802833]
Deter HC, Herzog W, Petzold E. The Heidelberg-Mannheim study: long-term follow-up of anorexia nervosa patients at the university medical center – background and preliminary results. In: Herzog W, et al., editors. The course of eating disorders: Long-term follow-up studies of anorexia and bulimia nervosa. Berlin: Springer; 1992. pp. 71–84.
Deter HC, Herzog W. Anorexia nervosa in a long-term perspective: Results of the Heidelberg-Mannheim Study. Psychosomatic Medicine. 1994;56(1):20–27. [PubMed: 8197311]
Deter HC, Kopp W, Zipfel S, Herzog W. Male anorexia nervosa patients in long-term follow-up. Nervenarzt. 1998;69(5):419–426. [PubMed: 9629558]
Dolan RJ, Mitchell J, Wakeling A. Structural brain changes in patients with anorexia nervosa. Psychological Medicine. 1988;18:349–353. [PubMed: 3399587]
Eating disorders: A guide for the primary care physician. Primary Care; Clinics in Office Practice. 2002;29(1):81–98. [PubMed: 11856660]
Eccles M, Mason J. How to develop cost-conscious guidelines. Health Technology Assessment. 2001;5(16):1–69. [PubMed: 11427188]
Eccles M, Freemantle N, Mason J. North of England evidence-based guideline development project: Methods of developing guidelines for efficient drug use in primary care. British Medical Journal. 1998;316:1232–1235. [PMC free article: PMC1112989] [PubMed: 9553004]
Eckert ED, Halmi KA, Marchi P, Grove W, Crosby R. Ten-year follow-up of anorexia nervosa: Clinical course and outcome. Psychological Medicine. 1995;25:143–156. [PubMed: 7792349]
Eckert ED, Goldberg SC, Halmi KA, Casper RC, Davis JM. Behaviour therapy in anorexia nervosa. British Journal of Psychiatry. 1979;134:55–59. [PubMed: 760924]
Eddy KT, Keel PK, Dorer DJ, Delinsky SS, Franko DL, Herzog DB. Longitudinal comparison of anorexia nervosa subtypes. International Journal of Eating Disorders. 2002;31(2):191–201. [PubMed: 11920980]
Eiro M, Katoh T, Watanabe T. Use of a proton-pump inhibitor for metabolic disturbances associated with anorexia nervosa. New England Journal of Medicine. 2002;346(2):140. [PubMed: 11784888]
Eisler I, Dare C, Hodes M, Russell G, Dodge E, Le Grange D. Family therapy for adolescent anorexia nervosa: The results of a controlled comparison of two family interventions. Journal of Child Psychology & Psychiatry & Allied Disciplines. 2000;41:727–736. [PubMed: 11039685]
Eldredge KL, Agras WS, Arnow B, Telch CF, Bell S, Castonguay L, Marnell M. The effects of extending cognitive-behavioural therapy for binge eating disorder among initial treatment non-responders. International Journal of Eating Disorders. 1997;21:347–352. [PubMed: 9138046]
Fairburn CG. A cognitive behavioural approach to the treatment of bulimia. Psychol Med. 1981;11(4):707–711. [PubMed: 6948316]
Fairburn CG, Marcus MD, Wilson GT. Cognitive-behavioral therapy for binge eating and bulimia nervosa: A comprehensive treatment manual. In: Fairburn CG, Wilson GT, editors. Binge eating: Nature, assessment and treatment. New York: Guilford Press; 1993. pp. 361–404.
Fairburn CG. Overcoming binge eating disorders. New York: Guilford Press; 1995.
Fairburn CG, Cooper Z, Doll HA, Norman P, O’Connor M. The natural course of bulimia nervosa and binge eating disorder in young women. Archives of General Psychiatry. 2000;57:659–665. [PubMed: 10891036]
Fairburn CG, Harrison PJ. Eating disorders. The Lancet. 2003;361:407–416. [PubMed: 12573387]
Fairburn CG, Peveler Bulimia nervosa and a stepped care approach to management. Gut. 1990;31(11):1220–1222. [PMC free article: PMC1378687] [PubMed: 2253902]
Fairburn CG, Cooper Z. Binge-eating, self-induced vomiting and laxative abuse: A community study. Psychol Med. 1984;14(2):401–410. [PubMed: 6588399]
Fairburn CG, Cooper PJ. Self-induced vomiting and bulimia nervosa: An undetected problem. Br Med J (Clin Res Ed) 1982;17(284(6323)):1153–1155. [PMC free article: PMC1496787] [PubMed: 6803873]
Fairburn CG, Welch SL, Norman PA, O’Connor ME, Doll HA. Bias and bulimia nervosa: How typical are clinic cases? Am J Psychiatry. 1996;153(3):386–391. [PubMed: 8610827]
Fairburn CG, Beglin Studies of the epidemiology of bulimia nervosa. Am J Psychiatry. 1990;147(4):401–408. [PubMed: 2180327]
Fairburn CG, Jones R, Peveler R, Hope RA. Psychotherapy and bulimia nervosa. Longer-term effects of interpersonal psychotherapy, behaviour therapy and cognitive behavior therapy. Archives of General Psychiatry. 1993;50:419–428. [PubMed: 8498876]
Fairburn CG, Jones R, Peveler R, Carr SJ, Solomon RA, O’Conner M, Burton J, Hope RA. Three psychological treatments for bulimia nervosa: A comparative trial. Archives of General Psychiatry. 1991;48:463–469. [PubMed: 2021299]
Fairburn CG, Jones R, Peveler R, Hope T, O’Connor M. Predictors of 12 month outcome in bulimia nervosa and the influence of attitudes to shape and weight. Journal of Consulting & Clinical Psychology. 1993;61:696–698. [PubMed: 8370866]
Fairburn CG, Kirk J, O’Conner M, Cooper PJ. A comparison of two psychological treatments for bulimia nervosa. Behaviour Research and Therapy. 1986;24:629–643. [PubMed: 3800834]
Fairburn CG, Norman PA, Welch SL, O’Connor M, Doll HA, Peveler R. A prospective study of outcome in bulimia nervosa and the long-term effects of three psychological treatments. Archives of General Psychiatry. 1995;52:304–312. [PubMed: 7702447]
Fairburn CG, Cowen PJ, Harrison PJ. Twin studies and the aetiology of eating disorders. International Journal of Eating Disorders. 1999;26:349–358. [PubMed: 10550776]
Fairburn CG, Cooper Z, Doll H, Norman P, O’Connor M. The natural course of bulimia nervosa and binge eating disorder in young women. Archives of General Psychiatry. 2000;57:659–665. [PubMed: 10891036]
Fairburn CG, Harrison PJ. Eating disorders. The Lancet. 2003;361(9355):407–416. [PubMed: 12573387]
Faris PL, Meller WH, Goodale RL, Oakman SA, Hofbauer RD, Marshall AM, Daughters RS, Banerjee-Stevens D, Eckert ED, Hartman BK. 5-HT3 antagonist therapy of bulimia nervosa: A peripherally active agent for a central nervous system eating disorder? Gastroenterology. 2000;119:271–272. [PubMed: 10889184]
Faris PL, Won Kim S, Meller WH, Goodale RL, Oakman SA, Hofbauer RD, Marshall AM, Daughters RS, Banerjee-Stevens D, Eckert ED, Hartman BK. Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial. The Lancet. 2000;355:792–797. [PubMed: 10711927]
Fassino S, Leombruni P, Daga G, Brustolin A, Migliaretti G, Cavallo F, Rovera G. Efficacy of citalopram in anorexia nervosa: A pilot study. European Neuropsychopharmacology. 2002;12(5):453–459. [PubMed: 12208563]
Fichter MM, Quadflieg N. Six-year course and outcome of anorexia nervosa. International Journal of Eating Disorders. 1999;26(4):359–385. [PubMed: 10550777]
Fichter MM, Leible K, Rief W, Brunner E, Schmidt-Auberger S, Engel RR. Fluoxetine versus placebo: A double-blind study with bulimic inpatients undergoing intensive psychotherapy. Pharmacopsychiatry. 1991;24:1–247. [PubMed: 2011615]
Fichter M, Kruger R, Rief W, Holland R, Dohne J. Fluvoxamine in prevention of relapse in bulimia nervosa: Effects on eating-specific psychopathology. Journal of Clinical Psychopharmacology. 1996;16:9–18. [PubMed: 8834413]
Field T, Schanberg S, Kuhn C, Field T, Fierro K, Henteleff T, Mueller C, Yando R, Shaw S, Burman I. Bulimic adolescents benefit from massage therapy. Adolescence. 1998;33:555–563. [PubMed: 9831872]
Fluoxentine for anorexia nervosa. Nurses Drug Alert. 2001;25:47–48.
Fluoxetine Bulimia Nervosa Collaborative Study Group. Fluoxetine in the treatment of bulimia nervosa. A multicenter, placebo-controlled, double-blind trial. Archives of General Psychiatry. 1992;49:139–147. [PubMed: 1550466]
Franko DL, Blais MA, Becker AE, Delinsky SS, Greenwood DN, Flores AT, Eddy KT, Herzog DB. Pregnancy complications and neonatal outcomes in women with eating disorders. American Journal of Psychiatry. 2001;158:1461–1466. [PubMed: 11532732]
Freeman C, Barry F, Dunkeld-Turnbull J, Henderson Controlled trial of psychotherapy for bulimia nervosa. British Medical Journal. 1988;296:521–525. [PMC free article: PMC2545167] [PubMed: 3126890]
Freeman C, Sinclair F, Turnball J, Annandale A. Psychotherapy for bulimia: A controlled study. Journal of Psychiatric Research. 1985;19:473–478.
Freund KM, Graham SM, Lesky LG, Moskovitz MA. Detection of bulimia nervosa in a primary care setting. Journal of General Internal Medicine. 1993;8(5):236–242. [PubMed: 8505681]
Garner, Garfinkel The Eating Attitudes Test: An index of the symptoms of anorexia nervosa. Psychol Med. 1979;9(2):273–279. [PubMed: 472072]
Garner DM, Olmsted MP, Polivy J. Development and validation of a multidimensional eating disorders inventory for anorexia nervosa and bulimia. Int J Eat Dis. 1983;2:15–34.
Garner DM, Rockert W, Davis R, Garner MV, Olmsted M, Eagle M. Comparison of cognitive-behavioural and supportive-expressive therapy for bulimia nervosa. American Journal of Psychiatry. 1993;150:37–46. [PubMed: 8417578]
Garvin V, Striegel-Moore RH. Health services research for eating disorders in the United States: A status report and a call to action. In: Striegel-Moore RH, et al., editors. Eating disorders: Innovative directions in research and practice. Washington DC: APA; 2001.
Geist R, Heinmaa M, Stephens D, Davis R, Katzman DK. Comparison of family therapy and family group psychoeducation in adolescents with anorexia nervosa. Canadian Journal of Psychiatry – Revue Canadienne de Psychiatrie. 2000;45:173–178. [PubMed: 10742877]
Goldberg SC, Eckert ED, Casper RC, Halmi KA, Davis JM, Roper MT. Factors influencing hospital differences in weight gain in anorexia nervosa. Journal of Nervous and Mental Disease. 1980;168(3):181–183. [PubMed: 7354320]
Goldberg SC, Casper RC, Eckert ED. Effects of cyproheptadine in anorexia nervosa. Psychopharmacology Bulletin. 1980;16:29–30.
Goldberg SC, Halmi KA, Eckert ED, Casper RC, Davis JM. Cyproheptadine in anorexia nervosa. British Journal of Psychiatry. 1979;134:67–70. [PubMed: 367480]
Goldbloom DS, Olmsted MP, Davies R, Shaw B. A randomised control trial of fluoxetine and cognitive behavioural therapy for bulimia nervosa: Short-term outcome. Behavioural Research and Therapy. 1997;35:803–811. [PubMed: 9299800]
Goldbloom DS, Kennedy SH. Medical complications of anorexia nervosa. In: Brownell KD, Fairburn CG, editors. Eating disorders and obesity: A comprehensive handbook. New York: Guilford; 1995.
Golden NH, Ashtari M, Kohn MR, Patel M, Jacobson MS, Fletcher A, Shenker IR. Reversibility of cerebral ventricular enlargement in anorexia nervosa, demonstrated by quantitative magnetic resonance imaging. Journal of Pediatrics. 1996;128:296–301. [PubMed: 8636835]
Golden NH. Osteopenia in adolescents with anorexia nervosa. Children’s Hospital Quaterly. 1992;4:143–148.
Goldfarb LA, Fuhr R, Tsujimoto RN, Fischman SE. Systematic desensitisation and relaxation as adjuncts in the treatment of anorexia nervosa: A preliminary study. Psychological Reports. 1987;60:511–518. [PubMed: 2884684]
Goldstein DJ, Wilson MG, Thomson VL, Potvin JH, Rampey AH. Long-term fluoxetine treatment of bulimia nervosa. British Journal of Psychiatry. 1995;166:660–666. [PubMed: 7620754]
Gordon CM, Grace E, Emans SJ, Feldman HA, Goodman E, Becker KA, Rosen CJ, Gundberg CM, LeBoff MS. Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: A randomised trial. Journal of Clinical Endocrinology and Metabolism. 2002;87:4935–4941. [PubMed: 12414853]
Gordon CM, Grace E, Emans J, Goodman E, Crawford MH, Leboff MS. Changes in bone turnover markers and menstrual function after short-term oral DHEA in young women with anorexia nervosa. Journal of Bone and Mineral Research. 1999;14:136–145. [PubMed: 9893076]
Gorin AA. A controlled trial of cognitive-behavioural therapy with and without spousal involvement for binge eating disorder. Dissertation Abstracts International: Section B: the Sciences & Engineering. 2001;61
Gowers S, Norton K, Halek C, Crisp AH. Outcome of out-patient psychotherapy in a random allocation treatment study of anorexia nervosa. International Journal of Eating Disorders. 1994;15:165–177. [PubMed: 8173562]
Gowers SG, Shore A. The stigma of eating disorders. Int J Clin Pract. 1999;53(5):386–388. [PubMed: 10695106]
Gowers SG, Shore A. Development of weight and shape concerns in the aetiology of eating disorders. Br J Psychiatry. 2001;179:236–242. [PubMed: 11532801]
Griffiths RA, Channon-Little L. The hypnotisability of patients with bulimia nervosa and partial syndromes participating in a controlled treatment outcome study. Contemporary Hypnosis. 1993;10:81–87.
Griffiths RA, Hadzi-Pavlovic D, Channon-Little L. A controlled evaluation of hypnobehavioural treatment for bulimia nervosa: Immediate pre-post treatment effects. European Eating Disorders Review. 1994;2:202–220.
Griffiths RA, Hadzi-Pavlovic D, Channon-Little L. The short-term follow-up effect of hypnobehavioural and cognitive behavioural treatment for bulimia nervosa. European Eating Disorders Review. 1996;4:12–31.
Griffiths RA, Hazi-Pavlovic D, Channon-Little L. Are there differences in response to psychological treatment for recruited and nonrecruited bulimic patients? European Eating Disorders Review. 1997;5:131–140.
Grinspoon S, Thomas E, Pitts S, Gross E, Mickley D, Miller K, Herzog D, Klibanski A. Prevalence and predictive factors for regional osteopenia in women with anorexia nervosa. Annals of Internal Medicine. 2000;133:790–794. [PMC free article: PMC3206091] [PubMed: 11085841]
Grinspoon S, Baum H, Lee K, Anderson E, Herzog D, Klibanski A. Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa. Journal of Clinical Endocrinology & Metabolism. 1996;81:3864–3870. [PubMed: 8923830]
Grinspoon S, Herzog D, Klibanski A. Mechanisms and treatment options for bone loss in anorexia nervosa. Psychopharmacol Bull. 1997;33(3):399–404. [PubMed: 9550884]
Grinspoon S, Thomas L, Miller K, Herzog D, Klibanski A. Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa. Journal of Clinical Endocrinology & Metabolism. 2002;87:2883–2891. [PubMed: 12050268]
Gross H, Ebert MH, Faden VB. A double-blind trial of Delta9-tetrahydrocannabinol in primary anorexia nervosa. Journal of Clinical Psychopharmacology. 1983;3:165–171. [PubMed: 6308069]
Halbreich U, Kahn LS. Selective oestrogen receptor modulators – current and future brain and behaviour applications. Expert Opinion in Pharmacotherapy. 2000;1:1385–1398. [PubMed: 11249472]
Hall A, Crisp AH. Brief psychotherapy in the treatment of anorexia nervosa. Outcome at one year. British Journal of Psychiatry. 1987;151:185–191. [PubMed: 3690108]
Hall A, Hay PJ. Eating disorder patient referrals from a population region 1977–1986. Psychol Med. 1991;21(3):697–701. [PubMed: 1946858]
Halmi KA, Goldberg SC, Casper RC, Eckert ED, Davis JM. Pre-treatment predictors of outcome in anorexia nervosa. British Journal of Psychiatry. 1979;134:71–78. [PubMed: 760925]
Halmi KA, Goldberg SC. Cyproheptadine in anorexia nervosa. Psychopharmacology Bulletin. 1978;14:31–33. [PubMed: 349601]
Halmi KA, Eckert E, Falk JR. Cyproheptadine, an antidepressant and weight-inducing drug for anorexia nervosa. Psychopharmacology Bulletin. 1983;19:103–105.
Halmi KA, Eckert E, LaDue TJ, Cohen J. Anorexia nervosa. Treatment efficacy of cyproheptadine and amitriptyline. Archives of General Psychiatry. 1986;43:177–181. [PubMed: 3511877]
Hart S, Field T, Hernandez-Reif M, Nearing G, Shaw S, Schanberg S, Kuhn C. Anorexia nervosa symptoms are reduced by massage therapy. Eating Disorders. 2001;9:289–299. [PubMed: 16864390]
Harwood MP, Newton T. Dental aspects of bulimia nervosa: Implications for the health care team. European Eating Disorders Review. 1995;3(2):93–102.
Hay PJ. Eating disorders: Anorexia nervosa, bulimia nervosa and related syndromes – An overview of assessment and management. Australian Prescriber. 1998;21(4):100–103.
Hay PJ, Marley J, Lemar S. Covert eating disorders: The prevalence, characteristics and help-seeking of those with bulimic eating disorders in general practice. Primary Care Psychiatry. 1998;4(2):95–99.
Hay PJ, Bacaltchuk J. Psychotherapy for bulimia nervosa and binging. Cochrane Database Syst Rev. 2003;(1):CD000562. [PubMed: 12535397]
Hebebrand J, Himmelmann GW, Herzog W, Herpertz-Dahlmann BM, Steinhausen HC, Amstein M, Seidel R, Deter HC, Remschmidt H, Schafer H. Prediction of low body weight at long-term follow-up in acute anorexia nervosa by low body weight at referral. American Journal of Psychiatry. 1997;154(4):566–569. [PubMed: 9090350]
Hebebrand J, Himmelmann GW, Wewetzer C, Gutenbrunner C, Heseker H, Schafer H, Remschmidt H. Body weight in acute anorexia nervosa and at follow-up assessed with percentiles for the body mass index: Implications of a low body weight at referral. International Journal of Eating Disorders. 1996;19(4):347–357. [PubMed: 9156688]
Hebebrand J, Wehmeier PM, Remschmidt H. Letter to the editor: Weight criteria for diagnosis of anorexia nervosa. American Journal of Psychiatry. 2000;157:1024. [PubMed: 10831496]
Hebebrand J, Himmelmann GW, Heseker H, et al. Use of percentiles for the body mass index in anorexia nervosa: diagnostic, epidemiological, and therapeutic considerations. International Journal of Eating Disorders. 1996;19:359–369. [PubMed: 9156689]
Herpertz-Dahlmann B, Muller B, Herpertz S, Heussen N, Hebebrand J, Remschmidt H. Prospective 10-year follow-up in adolescent anorexia nervosa – course, outcome, psychiatric comorbidity and psychosocial adaptation. Journal of Child Psychology and Psychiatry. 2001;42(5):603–612. [PubMed: 11464965]
Herzog DB, Keller MB, Sacks NR, Yeh CJ, Lavori PW. Psychiatric comorbidity in treatment-seeking anorexics and bulimics. J Am Acad Child Adolesc Psychiatry. 1992;31(5):810–818. [PubMed: 1400111]
Herzog DB, Nussbaum KM, Marmor AK. Comorbidity and outcome in eating disorders. Psychiatric Clinics of North America. 1996;19(4):843–859. [PubMed: 9045226]
Herzog W, Deter HC, Fiehn W, Petzold E. Medical findings and predictors of long-term physical outcome in anorexia nervosa: A prospective, 12-year follow-up study. Psychological Medicine. 1997;27(2):269–279. [PubMed: 9089820]
Herzog W, Greenwood DN, Dorer DJ, et al. Mortality in eating disorders: A descriptive study. International Journal of Eating Disorders. 2000;28:20–26. [PubMed: 10800010]
Herzog W, Schellberg D, Deter HC. First recovery in anorexia nervosa patients in the long-term course: A discrete-time survival analysis. Journal of Consulting and Clinical Psychology. 1997;65(1):169–177. [PubMed: 9103746]
Herzog T, Hartmann A, Falk C. The short-term effects of psychodynamic in-patient treatment of anorexia nervosa with and without an explicit focus on eating pathology – A controlled study. Psychotherapie Psychosomatik Medizinische Psychologie. 1996;46:11–22.
Herzog W, Deter HC, Fiehn W, Petzold E. Medical findings and predictors of long-term physical outcome in anorexia nervosa – A prospective, 12-year follow-up study. Psychological Medicine. 2003;27:269–279. [PubMed: 9089820]
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine. 2002;21(11):1539–1558. [PubMed: 12111919]
Hodes M, Timimi S, Robinson P. Children of mothers with eating disorders. A preliminary study. European Eating Disorders Review. 1997;5:1–24.
Hoek HW. The incidence and prevalence of anorexia nervosa in primary care. Psychological Medicine. 1991;21:455–460. [PubMed: 1876650]
Hoek HW. Distribution of eating disorders. In: Maj M, et al., editors. Eating disorders. John Wiley & Sons Ltd; 2003.
Hoek HW. The incidence and prevalence of anorexia nervosa in primary care. Psychological Medicine. 1991;21:455–460. [PubMed: 1876650]
Holderness CC, Brooks-Gunn J, Warren MP. Co-morbidity of eating disorders and substance abuse review of the literature. International Journal of Eating Disorders. 1994;16(1):1–34. [PubMed: 7920577]
Horne RL, Ferguson JM, Pope HG, Hudson JI, Lineberry CG, Ascher J, Cato A. Treatment of bulimia with bupropion: A multicenter controlled trial. Journal of Clinical Psychiatry. 1988;49:262–266. [PubMed: 3134343]
Howard WT, Evans KK, Quintero-Howard CV, Bowers WA, Andersen AE. Predictors of success or failure of transition to day hospital treatment for inpatients with anorexia nervosa. American Journal of Psychiatry. 1999;156(11):1697–1702. [PubMed: 10553731]
Howlett M, McClelland L, Crisp AH. The cost of illness that defies. Postgraduate Medical Journal. 1995;71:36–39. [PMC free article: PMC2398304] [PubMed: 8552529]
Hsu LK, Crisp AH, Callender JS. Psychiatric diagnoses in recovered and unrecovered anorectics 22 years after onset of illness: A pilot study. Compr Psychiatry. 1992;33(2):123–127. [PubMed: 1544296]
Hsu LK. Outcome of bulimia nervosa. In: Brownell KD, Fairburn CG, editors. Eating disorders and obesity. 1995. pp. 238–246.
Hsu LK, Rand W, Sullivan S, Liu DW, Mulliken B, McDonagh B, Kaye WH. Cognitive therapy, nutritional therapy and their combination in the treatment of bulimia nervosa. Psychological Medicine. 2001;31:871–879. [PubMed: 11459384]
Hsu LK, Crisp AH, Harding B. Outcome of anorexia nervosa. The Lancet. 1979:61–65. [PubMed: 84126]
Hudson JI, McElroy S, Raymond NC, Crow S, Keck PE, Carter MD, Mitchell JE, Strakowski MD, Pope HG, Coleman BS, Jonas JM. Fluvoxamine in the treatment of binge-eating disorder: A multicenter placebo-controlled, double-blind trial. American Journal of Psychiatry. 1998;155:1756–1762. [PubMed: 9842788]
Huseman CA, Pearson PH, Madison J, Leuschen MP. Bulimia as a form of self-addiction: Treatment with naltrexone hydrochloride (Trexan(TM)) – a pilot study. Clinical Trials Journal. 1990;27:77–83.
Iketani T, Kiriike N, Nakanishi S, Nakasuji T. Effects of weight gain and resumption of menses on reduced bone density in patients with anorexia nervosa. Biological Psychiatry. 1995;37:521–527. [PubMed: 7619974]
Irwin M. Early onset anorexia nervosa. Southern Medical Journal. 1984;77:611–614. [PubMed: 6719165]
Isner JM, Roberts WC, Heymsfield SB, Yageer J. Anorexia nervosa and sudden death. Annals of Internal Medicine. 1985;102:49–52. [PubMed: 3966745]
Ivarsson T, Rastam M, Wentz E, Gillberg IC, Gillberg C. Depressive disorders in teenage-onset anorexia nervosa: A controlled longitudinal, partly community-based study. Comprehensive Psychiatry. 2000;42(5):398–403. [PubMed: 11011838]
Jacobi C, Dahme D, Dittmann R. Cogntive-behavioural, fluoxetine and combined treatment for bulimia nervosa: Short-and long-term results. European Eating Disorders Review. 2002;10:179–198.
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomised clinical trials: Is blinding necessary? Controlled Clinical Trials. 1996;17(1):1–12. [PubMed: 8721797]
Jansen A, Elgersma H, Nederkoorn C, Smeets T. What makes treatment of bulimia nervosa successful?. Paper presented at the European Association for Cognitive and Behaviour Therapies Congress; 18–21 September; Maastricht. 2002.
Jansen A, Van den Hout MA, De Loof C, Zandbergen J, Griez E. A case of bulimia successfully treated by cue exposure. J Behav Ther Exp Psychiatry. 1989;20(4):327–332. [PubMed: 2576871]
Johnson WG, Jarrell MP, Chupurdia KM, Williamson DA. Repeated binge/purge cycles in bulimia nervosa: Role of glucose and insulin. Int J Eat Disord. 1994;15(4):331–341. [PubMed: 8032348]
Johnson JG, Spitzer RL, Williams JB. Health problems, impairment and illnesses associated with bulimia nervosa and binge eating disorder among primary care and obstetric gynaecology patients. Psychological Medicine. 2001;31:1455–1466. [PubMed: 11722160]
Jones R, Peveler R, Hope RA, Fairburn CG. Changes during treatment for bulimia nervosa: A comparison of three psychological treatments. Behaviour Research and Therapy. 1993 4797786975485. [PubMed: 8333822]
Kachele H, Kordy H, Mattias R. Research Group Treat. Therapy amount and outcome of in-patient psychodynamic treatment of eating disorders in Germany: Data from a multi-center study. Psychotherapy Research. 2001;11(3):239–257.
Kachele H. Eine multizentrishe Studie zu Aufwand und Erfolg bei psychodynamischer Therapie von Essstorungen. Psychotherapy, Psychosomatik, Midizinische Psychologie. 1999;49:100–108. [PubMed: 10373765]
Kanerva R, Rissanen A, Sarna S. Fluoxetine in the treatment of anxiety, depressive symptoms and eating-related symptoms in bulimia nervosa. Journal of Psychiatry. 1994;49:237–242.
Kaplan AS. Psychological treatments for anorexia nervosa: A review of published studies and promising new directions. Canadian Journal of Psychiatry. 2002;47:235–242. [PubMed: 11987474]
Kaplan DW, Blythe M, Diaz A, Feinstein RA, Fisher MM, Klein JD, et al. Identifying and treating eating disorders. Pediatrics. 2003;111(1):204–211.
Katz RL, Keen CL, Litt IF, Hurley LS, Kellams-Harrison KM, Glader LJ. Zinc deficiency in anorexia nervosa. Journal of Adolescent Health Care. 1987;8:400–406. [PubMed: 3312133]
Katzman DK, Lambe EK, Mikulis DJ, Ridgley JN, Goldbloom DS, Zipursky RB. Cerebral gray matter and white matter volume deficits in adolescent girls with anorexia nervosa. Journal of Pediatrics. 1996;129:794–803. [PubMed: 8969719
At the suggestion of her pediatrician, “Rachel,” a 19-year-old college freshman at a competitive liberal arts college, was brought by her parents for psychiatric evaluation during spring break. According to her parents, Rachel had lost 16 lb since her precollege physical the previous August, falling to a weight of 104 lb at a height of 5 feet, 5 inches. Rachel’s chief complaint was that “everyone thinks I have an eating disorder.” She explained that she had been a successful student and field hockey player in high school. Having decided not to play field hockey in college, she began running several mornings each week during the summer and “cut out junk food” to protect herself from gaining “that freshman 10.” Rachel lost a few pounds that summer and received compliments from friends and family for looking so “fit.” She reported feeling more confident and ready for college than she had expected as the summer drew to a close. Once she began school, Rachel increased her running to daily, often skipped breakfast in order to get to class on time, and selected from the salad bar for her lunch and dinner. She worked hard in school, made the dean’s list the first semester, and announced to her family that she had decided to pursue a premed program. When Rachel returned home for Christmas vacation, her family noticed that she looked thin and tired. Despite encouragement to catch up on rest, she awoke early each morning to maintain her running schedule. She displayed a newfound interest in cooking and spent much of the day planning, shopping, and preparing dinner for her family. Rachel returned to school in January and thought she might be developing depression. Courses seemed less interesting, and she wondered whether the college she attended was right for her after all. She was sleeping less well and felt cold much of the day. Rachel’s parents asked her to step on the bathroom scale the night she returned home for spring break. Rachel was surprised to learn that her weight had fallen to 104 lb, and she agreed to a visit to her pediatrician, who found no evidence of a general medical illness and recommended a psychiatric consultation. Does Rachel have anorexia nervosa? If so, how should she be treated?
Anorexia nervosa is a serious mental illness characterized by the maintenance of an inappropriately low body weight, a relentless pursuit of thinness, and distorted cognitions about body shape and weight. Anorexia nervosa commonly begins during middle to late adolescence, although onsets in both prepubertal children and older adults have been described. Anorexia nervosa has a mortality rate as high as that seen in any psychiatric illness (1) and is associated with physiological alterations in virtually every organ system, although routine laboratory test results are often normal and physical examination may reveal only marked thinness.
DSM-IV (2) lists four criteria for the diagnosis of anorexia nervosa:
1. Refusal to maintain body weight at or above a minimally normal weight for age and height
2. Intense fear of gaining weight or becoming fat, even though underweight
3. Disturbance in the way in which one’s body weight or shape is experienced, undue influence of body weight or shape on self-evaluation, or denial of the seriousness of the current low body weight
4. In postmenarchal females, amenorrhea (i.e., the absence of at least three consecutive menstrual cycles)
DSM-IV describes two subtypes of anorexia nervosa—the restricting subtype, consisting of those individuals whose eating behavior is characterized by restriction of type and quantity of food without binge eating or purging behaviors, and the binge-purge subtype, consisting of those who also exhibit binge eating and/or purging behaviors, such as vomiting or misuse of laxatives.
The DSM-IV criteria are most easily applied when patients are both sufficiently ill to fulfill all four diagnostic criteria and able to describe their ideation and behavior accurately. However, because ambivalence and denial frequently lead those with anorexia nervosa to minimize their symptoms, the clinician must make inferences about mental state and behavior.
An additional problem in diagnosis is that many individuals meet some but not all of the formal diagnostic criteria. For example, some women who meet all other criteria for anorexia nervosa continue to report some spontaneous menstrual activity. In a community-based sample of 84 female patients with full- or partial-syndrome anorexia nervosa, those with amenorrhea were not statistically different from those without across a number of clinical variables (3) , which raises questions about the utility of this diagnostic criterion (4 , 5) .
Proper diagnosis of any condition that includes low weight and restrictive eating must include consideration of other psychiatric and medical conditions that include these problems. Psychotic disorders, including schizophrenia and schizoaffective and delusional disorders, as well as anxiety disorders, such as obsessive-compulsive disorder, can include symptoms of food avoidance and distorted beliefs about one’s body. Medical conditions, including endocrine disturbances (such as thyroid disease and diabetes mellitus), gastrointestinal disturbances (such as inflammatory bowel and celiac disease), infections (such as hepatitis), and neoplastic processes may present with weight loss and should be considered when evaluating a patient for a possible eating disorder.
Anorexia nervosa has been recognized for centuries. Sir William Gull coined the term anorexia nervosa in 1873, but Richard Morton likely offered the first medical description of the condition in 1689 (6 , 7) . Despite its long-standing recognition, remarkably little is known about the etiology of, and effective treatment for, anorexia nervosa. A 2002 review in the American Journal of Psychiatry concluded that little progress was made during the second half of the 20th century in understanding the etiology, prognosis, or treatment of the disorder (8) .
Prevalence rates for anorexia nervosa are generally described as ranging from 0.5% to 1.0% among females (9 , 10) , with males being affected about one-tenth as frequently (10 , 11) . A recent study describing a large population-based cohort of Swedish twins born between 1935 and 1958 found the overall prevalence of anorexia nervosa among the 31,406 study participants to be 1.20% and 0.29% for females and males, respectively; the prevalence of anorexia nervosa in both sexes was greater among those born after 1945 (12) .
The identification of risk factors for anorexia nervosa is challenging because the low incidence of the disorder makes the conduct of prospective studies of sufficient size very difficult. A variety of possible risk factors have been identified, including early feeding difficulties, symptoms of anxiety, perfectionistic traits, and parenting style, but none can be considered to have been conclusively demonstrated (13 , 14) . Similarly, cultural factors undoubtedly play some role in the development of anorexia nervosa, although the disorder’s long history and its presence in regions around the globe (15 – 18) suggest that factors other than culture provide central contributions to the development of the disorder. In fact, one review that considers historical reports of eating disorders, data regarding changing incidence rates of eating disorders over time, and the prevalence of eating disorders in non-Western cultures concludes that anorexia nervosa is not a culture-bound syndrome (19) . Genetic factors are increasingly accepted as important contributors to the risk of anorexia nervosa. Twin studies of eating disorders have consistently found that a significant fraction of the variability in the occurrence of anorexia nervosa can be attributed to genetic factors, with heritability estimates ranging from 33% to 84% (20) .
Course of Illness
The course of anorexia nervosa is highly variable, with individual outcomes ranging from full recovery to a chronic and severe psychosocial disability accompanied by physical complications and death. Intervention early in the course of illness and full weight restoration appear to be associated with the best outcomes. Adolescent patients have a better prognosis than do adults. One-year relapse rates after initial weight restoration approach 50% (21) . Intermediate and long-term follow-up studies examining clinical samples find that while a significant fraction of patients achieve full psychological and physical recovery, at least 20% continue to meet full criteria for anorexia nervosa on follow-up assessment, with many others reporting significant residual eating disorder symptoms, even if they do not meet full criteria for anorexia nervosa (22) .
A multitude of biological disturbances may occur in underweight patients, but most appear to be normal physiological responses to starvation. Clinically significant abnormalities may develop in the cardiovascular, gastrointestinal, reproductive, and fluid and electrolyte systems (23) . These abnormalities usually do not require specific treatment beyond refeeding, and they return to normal on weight restoration. A worrisome possible exception is reduced bone density; since peak bone density is normally achieved during young adulthood, a prolonged episode of anorexia nervosa during this development stage may have a long-term impact on the risk of osteoporosis.
The striking physical and behavioral characteristics of anorexia nervosa have prompted the development of a variety of neurobiological hypotheses over the years. Recently, results of several investigations have suggested that abnormalities in CNS serotonin function may play a role in the development and persistence of the disorder (24 , 25) . Notably, studies of long-term weight-recovered patients have described indications of increased serotonin activity, such as elevated levels of the serotonin metabolite 5-hydroxyindoleacetic acid in the CSF (26) and reduced binding potential of 5-HT 2A receptors, suggestive of higher levels of circulating CNS serotonin, in several brain regions (27) .
Kaye and colleagues (28) hypothesize that individuals with anorexia nervosa may have a trait disturbance characterized by high levels of CNS serotoninergic activity leading to symptoms of anxiety that are relieved by dieting, which leads to a reduction in serotonin production. However, this provocative hypothesis is based on assessments conducted after the onset of illness, which therefore cannot distinguish a predisposing trait from a long-lasting consequence of anorexia nervosa.
Another recent line of inquiry into the biological underpinnings of anorexia nervosa focuses on the perfectionistic and rigid behavioral style, including repetitive and stereotyped behaviors, characteristic of the syndrome. Investigators have hypothesized that these behaviors may result from a propensity to extreme fear conditioning and resistance to fear extinction (29) , suggesting that abnormalities may be present in limbic structures known to be involved in the acquisition of conditioned fear behavior. Other investigators have proposed that difficulties of individuals with anorexia nervosa in changing maladaptive behavior may relate to problems with set shifting, a function mediated by corticostriatothalamocortical neural circuits (30 , 31) .
Engaging a patient with anorexia nervosa to participate fully in the psychiatric evaluation may present a greater challenge than would be the case for patients with other disorders, including other eating disorders such as bulimia nervosa or binge eating disorder. Patients with anorexia nervosa often present for evaluation not because of their own interest in symptom relief but because of the concerns of family, friends, or health care providers. It may be necessary to obtain additional information from family members or others who know the patient well.
In addition, during the evaluation, it may be helpful to identify symptoms of the illness that are most likely to be ego-dystonic for the particular patient. Patients commonly minimize their concerns about low weight, but they may be more concerned, and therefore more likely to participate in the evaluation, if they recognize poor concentration, increased irritability, low bone density, hair loss, or feeling cold as developments associated with their restrictive eating pattern.
Medical issues should be reviewed, including weight and menstrual history. A complete review of systems is indicated, as anorexia nervosa can manifest a multitude of disturbances, including cardiovascular symptoms (e.g., bradycardia and other arrhythmias, including QTc prolongation, and hypotension), gastrointestinal symptoms (e.g., slow motility, esophageal inflammation associated with purging), endocrinologic symptoms (low estrogen in females, low testosterone in males, osteopenia, and osteoporosis), and dermatologic changes, such as the development of a layer of fine hair (lanugo) on the face and extremities.
The evaluation should include specific questions about eating behaviors, including the number and content of all meals and snacks on a recent day. The clinician should inquire about 1) restricting behaviors, including limiting permissible foods, as well as decreasing caloric amounts; 2) binge eating; 3) purging behaviors, including vomiting and misuse of laxatives and diuretics; and 4) exercise and hyperactive behaviors, including preferential walking and standing.
Given patients’ reluctance to endorse all of the diagnostic symptoms of anorexia nervosa on first meeting, the clinician may do well to identify the problem as “low weight” and explain that the treatment needs to include weight restoration, whether or not the patient meets full criteria for anorexia nervosa. Patients and their families are generally very interested in data from the World War II Minnesota study of semistarvation that documented the association between starvation and the development of psychological symptoms frequently identified with anorexia nervosa, such as depression, anxiety, obsessionality about food, and rigidity about eating behaviors (32) . The clinician may have better results engaging the patient with the identification of symptoms that are commonly associated with the state of starvation and that the patient has likely found troubling (such as thinking constantly about food) and therefore worth resolving.
All current treatment guidelines for anorexia nervosa emphasize weight restoration. There is no clearly defined algorithm for how to accomplish this goal, although common practice includes the selection of the least restrictive treatment setting that is likely to be effective. The APA practice guideline on treatment of eating disorders suggests that highly structured treatments are often needed to achieve weight gain for patients at weights <85% ideal body weight (33) . Hospital-based treatments may be used when weight is significantly low (e.g., <75% of ideal body weight) or when there has been rapid weight loss or medical signs of malnutrition, including significant bradycardia, hypotension, hypothermia, and so on.
Generally, outpatient treatments rely on a team of professionals. Medical monitoring, including weight and laboratory assessment, may be provided by an internist or pediatrician; psychological support is offered by a psychiatrist or other therapist; and nutritional counseling from a dietitian or nutritionist is often included. The team is generally led by the medical or psychiatric clinician—typically the one with the greatest expertise in the management of eating disorders.
Effective treatments generally assess outcome by weight and behavioral change. Nonspecific support needs to be paired with expectation of progress in measurable medical, behavioral, and psychological symptoms. Weight restoration is generally associated with improvement in a variety of psychological areas, including mood and anxiety symptoms (34 , 35) . In contrast, psychological improvement without accompanying changes in weight and eating behavior is of limited value. Patients and families should be informed about the physiology of weight gain, including the substantial number of calories required daily.
A family-based outpatient treatment for anorexia nervosa, also called the “Maudsley method,” may be helpful for younger patients (36) . This approach empowers the parents of a patient with anorexia nervosa to refeed their child, renegotiate the relationship between child and parents to involve issues other than food, and help their child resume normal adolescent development without an eating disorder. Several preliminary studies have shown promising results for family therapy with adolescent patients (37 , 38) .
For patients with anorexia nervosa who do not respond to outpatient treatments or those who do not have specialized outpatient treatments available in their vicinity, more structured treatments such as inpatient or partial hospital (day treatment) programs may be necessary. Structured treatments generally include observation during and after meals together with a consistently applied behavioral program that reinforces weight gain and normal eating behaviors. In recent years, the length of hospital stay for anorexia nervosa has decreased substantially because of economic limitations imposed by third-party payers; nonetheless, hospital programs can achieve a rate of weight gain of 2–4 pounds per week during active treatment (39) .
Controlled Treatment Trials
While structured settings have been used successfully for weight restoration treatments, there is little empirical support for a specific level of care or a particular psychosocial treatment for anorexia nervosa. As mentioned, a family-based approach appears promising for children and adolescents with anorexia nervosa; family therapy has been reported to be superior to individual therapy in two randomized controlled trials for adolescents with anorexia nervosa (40 , 41) . For adults with anorexia nervosa, a small study by Pike and colleagues (42) found cognitive behavior therapy superior to nutritional counseling in preventing relapse after hospital-based weight restoration. A recent study by McIntosh et al. (43) provocatively suggested that a patient-centered nonspecific supportive therapy may have been more helpful than cognitive behavior therapy or interpersonal therapy, as measured by a global rating of anorexia nervosa symptoms, in a sample of 56 underweight women with anorexia nervosa receiving treatment over a minimum of 20 weeks; unfortunately, the amount of weight gain was modest and not significantly different among the three study treatments.
Randomized controlled trials of medications for patients with anorexia nervosa have consistently reported disappointing results. Several psychopharmacologic agents have been studied, without identification of clear benefit, although studies have been limited by small sample sizes and the fact that most of the trials have been conducted in hospital settings where other treatment interventions are offered in addition to study medication (44) . While it has been suggested that psychotropic medications are rendered ineffective in underweight patients by the biological impact of starvation, a recent study comparing fluoxetine and placebo in weight-restored patients notably found no significant benefit to medication during the year following nutritional rehabilitation (45) .
Summary and Recommendations
Although recognized for centuries, anorexia nervosa remains enigmatic, often difficult to treat, and potentially lethal. The current approach to treatment includes careful medical assessment, ongoing medical and weight monitoring, and behaviorally oriented treatment aimed at normalizing weight and eating behaviors. Family-based treatment appears promising for younger patients.
With Rachel, the patient in the vignette, her typical presentation, her low weight (corresponding to a body mass index of 17.3), and her reluctance to restore her weight to its previously healthy level led the evaluating psychiatrist to conclude that Rachel indeed had anorexia nervosa. The psychiatrist recommended that Rachel attempt outpatient treatment but explained to her and her family that many patients require more structured settings for successful weight restoration. The psychiatrist recommended that Rachel see an eating disorder specialist knowledgeable about the characteristics of anorexia nervosa and experienced in dealing with the challenges of its treatment. The outpatient treatment plan included weekly psychotherapy sessions, along with regular visits with her pediatrician and a nutritionist. Although Rachel had complained of “depression,” the psychiatrist elected not to prescribe antidepressant medication, as there is no evidence of its utility in anorexia nervosa, and weight gain in this disorder is known to lead to improvement in mood. In the meetings with Rachel, the psychiatrist used cognitive behavior therapy techniques to help her in reevaluating her assumptions that low weight was somehow essential to her sense of self-worth. Treatment outcome was assessed by changes in weight and eating behavior. Rachel’s family participated by helping to supervise meals at the start of treatment and offering her more autonomy around eating as she made progress. Rachel was asked to gain weight at a rate of >1 lb per week and knew that failure to meet this goal would lead to transfer of treatment to a more structured setting. Rachel reached and maintained her premorbid weight and was able to return to school 6 months after initial presentation.
Received July 19, 2007; accepted Aug. 6, 2007 (doi: 10.1176/appi.ajp.2007.07071151). From the Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York; and the Eating Disorders Research Unit, New York State Psychiatric Institute, New York. Address correspondence and reprint requests to Dr. Attia, New York State Psychiatric Institute, 1051 Riverside Dr., Unit 98, New York, NY 10032; email@example.com (e-mail).
CME Disclosure: Dr. Attia has received research support from Pfizer and Eli Lilly. Dr. Walsh has received research support from Abbott Pharmaceuticals.
APA policy requires disclosure by CME authors of unapproved or investigational use of products discussed in CME programs. Off-label use of medications by individual physicians is permitted and common. Decisions about off-label use can be guided by scientific literature and clinical experience.
|1.||Sullivan PF: Mortality in anorexia nervosa. Am J Psychiatry 1995; 152:1073–1074|
|2.||American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC, American Psychiatric Association, 1994|
|3.||Garfinkel PE, Lin E, Goering P, Spegg C, Goldbloom D, Kennedy S, Kaplan AS, Woodside DB: Should amenorrhea be necessary for the diagnosis of anorexia nervosa? evidence from a Canadian community sample. Br J Psychiatry 1996; 168:500–506|
|4.||Cachelin F, Maher B: Is amenorrhea a critical criterion for anorexia nervosa? J Psychosom Res 1998;44:435–440|
|5.||Watson T, Andersen A: A critical examination of the amenorrhea and weight criteria for diagnosing anorexia nervosa. Acta Psychiatr Scand 2003;108:175–182|
|6.||Pearce JM: Richard Morton: origins of anorexia nervosa. Eur Neurol 2004; 52:191–192|
|7.||Silverman JA: Sir William Gull (1819–1890): limner of anorexia nervosa and myxoedema: an historical essay and encomium. Eat Weight Disord 1997; 2:111–116|
|8.||Steinhausen H-C: The outcome of anorexia nervosa in the 20th century. Am J Psychiatry 2002; 159:1284–1293|
|9.||Hoek HW, van Hoeken D: Review of the prevalence and incidence of eating disorders. Int J Eat Disord 2003; 34:383–396|
|10.||Hudson JI, Hiripi E, Pope HG Jr, Kessler RC: The prevalence and correlates of eating disorders in the National Comorbidity Survey replication. Biol Psychiatry 2007; 61:348–358|
|11.||Lucas AR, Beard CM, O’Fallon WM, Kurland LT: 50-year trends in the incidence of anorexia nervosa in Rochester, Minn: a population-based study. Am J Psychiatry 1991; 148:917–922|
|12.||Bulik CM, Sullivan PF, Tozzi F, Furberg H, Lichtenstein P, Pedersen NL: Prevalence, heritability, and prospective risk factors for anorexia nervosa. Arch Gen Psychiatry 2006; 63:305–312|
|13.||Jacobi C, Hayward C, de Zwaan M, Kraemer HC, Agras WC: Coming to terms with risk factors for eating disorders: application of risk terminology and suggestions for a general taxonomy: Psychol Bull 2004; 130:19–65|
|14.||Striegel-Moore RH, Bulik CM: Risk factors for eating disorders. Am Psychologist 2007; 62:181–198|
|15.||Lee HY, Lee EL, Pathy P, Chan YH: Anorexia nervosa in Singapore: an eight-year retrospective study. Singapore Med J 2005; 46:275–281|
|16.||Njenga FG, Kangethe RN: Anorexia nervosa in Kenya. East Afr Med J 2004; 81:188–193|
|17.||Bennett D, Sharpe M, Freeman C, Carson A: Anorexia nervosa among female secondary school students in Ghana. Br J Psychiatry 2004; 185:312–317|
|18.||Hoek HW, van Harten PN, Hermans KME, Katzman MA, Matroos GE, Susser ES: The incidence of anorexia nervosa on Curaçao. Am J Psychiatry 2005; 162:748–752|
|19.||Keel PK, Klump KL: Are eating disorders culture-bound syndromes? implications for conceptualizing their etiology. Psychol Bull 2003; 129:747–769|
|20.||Bulik CM: Exploring the gene-environment nexus in eating disorders. J Psychiatry Neurosci 2005; 30:335–339|
|21.||Pike KM: Long-term course of anorexia nervosa: response, relapse, remission, and recovery. Clin Psychol Rev 1998; 18:447–475|
|22.||Fisher M: The course and outcome of eating disorders in adults and in adolescents: a review. Adolesc Med 2003; 14:149–158|
|23.||Walsh BT: Eating disorders, in Harrison’s Principles of Internal Medicine, 17th ed. Edited by Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL. New York, McGraw-Hill (in press)|
|24.||Kaye WH, Frank GK, Bailer UF, Henry SE: Neurobiology of anorexia nervosa: clinical implications of alterations of the function of serotonin and other neuronal systems. Int J Eat Disord 2005; 37(suppl):S15–S19|
|25.||Attia E, Wolk S, Cooper T, Glasofer D, Walsh BT: Plasma tryptophan during weight restoration in patients with anorexia nervosa. Biol Psychiatry 2005; 57:674–678|
|26.||Kaye WH, Gwirtsman HE, George DT, Ebert MH: Altered serotonin activity in anorexia nervosa after long-term weight restoration: does elevated cerebrospinal fluid 5-hydroxyindoleacetic acid level correlate with rigid and obsessive behavior? Arch Gen Psychiatry 1991; 48:556–562|
|27.||Frank GK, Kaye WH, Meltzer CC, Price JC, Greer P, McConaha C, Skovira K: Reduced 5-HT 2A receptor binding after recovery from anorexia nervosa. Biol Psychiatry 2002; 52:896–906|
|28.||Kaye WH, Barbarich NC, Putnam K, Gendall KA, Fernstrom J, Fernstrom M, McConaha CW, Kishore A: Anxiolytic effects of acute tryptophan depletion in anorexia nervosa. Int J Eat Disord 2003; 33:257–267|
|29.||Strober M: Pathologic fear conditioning and anorexia nervosa: on the search for novel paradigms. Int J Eat Disord 2004; 35:504–508|
|30.||Holliday J, Tchanturia K, Landau S, Collier D, Treasure J: Is impaired set-shifting an endophenotype of anorexia nervosa? Am J Psychiatry 2005; 162:2269–2275|
|31.||Steinglass J, Walsh BT, Stern Y: Set shifting deficit in anorexia nervosa. J Int Neuropsychol Soc 2006; 12:431–435|
|32.||Schiele BC, Brozek J: “Experimental neurosis” resulting from semistarvation in man. Psychosom Med 1948; 10:31–50|
|33.||American Psychiatric Association: Practice Guideline for the Treatment of Patients With Eating Disorders, 3rd ed. Am J Psychiatry 2006; 163(Jul suppl)|
|34.||Meehan KG, Loeb KL, Roberto CA, Attia E: Mood change during weight restoration in patients with anorexia nervosa. Int J Eat Disord 2006; 39:587–589|
|35.||Attia E, Haiman C, Walsh BT, Flater SR: Does fluoxetine augment the inpatient treatment of anorexia nervosa? Am J Psychiatry 1998; 155:548–551|
|36.||Lock J, le Grange D, Agras WS, Dare C: Treatment Manual for Anorexia Nervosa: A Family Based Approach. New York, Guilford, 2001|
|37.||Lock J, le Grange D, Forsberg S, Hewell K: Is family therapy useful for treating children with anorexia nervosa? results of a case series. J Am Acad Child Adolesc Psychiatry 2006; 45:1323–1328|
|38.||Lock J, Agras WS, Bryson S, Kraemer HC: A comparison of short- and long-term family therapy for adolescent anorexia nervosa. J Am Acad Child Adolesc Psychiatry 2005; 44:632–639|
|39.||Guarda AS, Heinberg LJ: Inpatient and partial hospital approaches to the treatment of eating disorders, in Handbook of Eating Disorders and Obesity. Edited by Thompson JK. Hoboken, NJ, John Wiley & Sons, 2004, pp 297–322|
|40.||Russell GF, Szmukler GI, Dare C, Eisler I: An evaluation of family therapy in anorexia nervosa and bulimia nervosa. Arch Gen Psychiatry 1987; 44:1047–1056|
|41.||Robin AL, Siegel PT, Moye AW, Gilroy M, Dennis AB, Sikand A: A controlled comparison of family versus individual therapy for adolescents with anorexia nervosa. J Am Acad Child Adolesc Psychiatry 1999; 38:1482–1489|
|42.||Pike KM, Walsh BT, Vitousek K, Wilson GT, Bauer J: Cognitive behavior therapy in the posthospitalization treatment of anorexia nervosa. Am J Psychiatry 2003; 160:2046–2049|
|43.||McIntosh VVW, Jordan J, Carter FA, Luty SE, McKenzie JM, Bulik CM, Frampton CMA, Joyce PR: Three psychotherapies for anorexia nervosa: a randomized, controlled trial. Am J Psychiatry 2005; 162:741–747|
|44.||Attia E, Schroeder L: Pharmacologic treatment of anorexia nervosa: where do we go from here? Int J Eat Disord 2005; 37(suppl):S60–S63|
|45.||Walsh BT, Kaplan AS, Attia E, Olmsted M, Parides M, Carter JC, Pike KM, Devlin MJ, Woodside B, Roberto CA, Rockert W: Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial. JAMA 2006; 295:2605–2612|